Related Experiment Video

Updated: Jul 18, 2026

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer
07:59

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

A review of vaccine clinical trials for non-small cell lung cancer

J Nemunaitis1, J Nemunaitis

  • 1Mary Crowley Medical Research Center, 60th Floor, 1717 Main St, Dallas, Texas 75201, USA. jnemunaitis@mcmrc.com

Expert Opinion on Biological Therapy
|December 8, 2006
PubMed

Insights

Cancer vaccines enhancing tumor recognition show promise for non-small cell lung cancer (NSCLC) patients. These approaches demonstrate safety with potential for prolonged stable disease and survival benefits.

Area of Science:

  • Oncology
  • Immunology
  • Vaccinology

Background:

  • Non-small cell lung cancer (NSCLC) remains a leading cause of cancer-related mortality.
  • Therapeutic cancer vaccines aim to enhance the host immune response against tumor antigens.
  • Improving antigen recognition is a key strategy for effective cancer immunotherapy.

Purpose of the Study:

  • To review current peptide-, gene-, and cell-based vaccine strategies for NSCLC.
  • To evaluate the clinical efficacy and safety of these investigational vaccines.
  • To identify promising vaccine candidates for further clinical development.

Main Methods:

  • Systematic review of published clinical trials and studies on NSCLC vaccines.
  • Analysis of data regarding vaccine toxicity, tumor response, and survival outcomes.
  • Comparison of vaccine efficacy against historical controls and low-dose comparator groups.

Main Results:

  • Vaccine approaches reviewed consistently demonstrated a lack of significant toxicity.
  • Prolonged stable disease, tumor shrinkage, and survival benefits were observed in patient subsets.
  • Specific vaccines like LBLP25, TGF-beta2 antisense gene vaccine, and GVAX showed encouraging results.

Conclusions:

  • Vaccines enhancing tumor antigen recognition represent a viable therapeutic strategy for NSCLC.
  • Several vaccine candidates warrant further investigation, including Phase III trials.
  • Immunotherapy with targeted vaccines holds potential for improving outcomes in NSCLC patients.

Related Concept Videos

Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...